

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## Single Technology Appraisal (STA)

## Belatacept for the prevention of organ rejection in kidney transplantation

## Provisional matrix of consultees and commentators

| Consultees  | Commentators (no right to submit or appeal)  |
|---|--|
| <p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Bristol-Myers Squibb Pharmaceuticals (belatacept)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• British Kidney Patient Association</li> <li>• British Organ Donor Society (BODY)</li> <li>• Chinese National Healthy Living Centre</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Kidney Alliance</li> <li>• Kidney Research UK</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• National Kidney Federation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Transplant Support Network</li> <li>• Transplant Trust</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Renal Industries</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association for Services to the Elderly</li> <li>• British Association of Urological Surgeons</li> <li>• British Geriatrics Society</li> <li>• British Renal Society</li> <li>• British Transplantation Society</li> <li>• British Urological Foundation</li> <li>• National Kidney Research Fund</li> <li>• Renal Association</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> </ul> | <p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Blood and Transplant</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• NHS Quality Improvement Scotland</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Kidney Patients Association</li> </ul> <p><u>Possible Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Actavis (mycophenolate mofetil)</li> <li>• Astellas Pharma (tacrolimus)</li> <li>• Dexcel-Pharma (ciclosporin)</li> <li>• Mylan (ciclosporin, mycophenolate mofetil)</li> <li>• Novartis Pharmaceuticals UK (basiliximab, ciclosporin and mycophenolate sodium)</li> <li>• Pfizer (sirolimus)</li> <li>• Roche Products (mycophenolate mofetil)</li> <li>• Sandoz (tacrolimus)</li> <li>• Teva UK (mycophenolate mofetil)</li> <li>• Winthrop Pharmaceuticals UK (mycophenolate mofetil)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Renal Group</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> |

National Institute for Clinical Excellence  
Provisional matrix for the appraisal of belatacept for the prevention of organ rejection in kidney transplantation

Issue date: February 2011

|  |  |
|--|--|
| <ul style="list-style-type: none"> <li>• Royal College of Physicians</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicines</li> <li>• Society for DGH Nephrologists</li> <li>• UK Renal Pharmacy Group</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS East Riding of Yorkshire</li> <li>• NHS Nottingham City</li> <li>• Welsh Assembly Government</li> </ul> | <ul style="list-style-type: none"> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Peninsula Technology Assessment Group (PenTAG)</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> |
|--|--|

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

**Definitions:**

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.